

#### **Disclaimer**

- This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of the Company to differ materially from the estimations expressed or implied herein.
- The Company does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does the Company accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast development.
- No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, none of the Company or any of its parent or subsidiary undertakings or any of such person's officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.

# Well Underway: Innovative Solutions Provider

**CEO Dietmar Siemssen** 



Transforming our Gerresheimer into a growth company as innovation leader and solution provider

### Successful on the Sustainable Growth Path

Key Take-Aways Q3 2021





**Boosting High Value Solutions:** ~ +30% yoy

Biologics: +30% yoy



**Sustain growth** momentum in the fourth quarter -

**Guidance confirmed** 

The core business consists of the Plastics & Devices and the Primary Packaging Glass divisions; for adjusted EBITDA purposes also including corporate functions/consolidation.

# **New Gerresheimer: Growth Along the Whole Portfolio**

**Leveraging Growth With the Right Product Solutions** 



#### **High Value Solutions Biological Solutions**



Global mega trends, e.g. biologics, boosting growth of High Value Solutions



Pharma Solutions/ **Underlying Business** 



Regional expansion balancing the global footprint



**Contract Manufacturing/ MedTech Solutions** 



Strong order intake laying the foundation for future growth



**Beauty Solutions & Others** 



Dynamic recovery in cosmetics – high value beauty solutions supporting margin development

## Leverage Beauty Solutions With our Pharma Skills

**Deep Dive Beauty Solutions: Cosmetic Goes Health** 

#### **Examples for anticipating global beauty trends through pharma expertise**



#### Deepen customer touch points to increase customer satisfaction and business growth

- Extension of customer touchpoint approach to all business areas across the whole organization
- Joint forces: innovate cross-divisional, cross-business unit

# Innovate on Solutions to Enlarge Beauty Portfolio

Cosmetics and Beauty Growth Opportunities in Tubular, Moulded and Plastics



#### **Beauty Solutions in Tubular**

- Newly developed pipettes as holistic solution in a rapidly growing market
- Cosmetic vials and ampoules



#### **Selective Segment**

- Premium options offer increase market share in selective segment
- Leveraging on investments into finishing solutions



#### **Sustainability & Beauty**

- Gx positioned as leading supplier of recycled glass.
- EcoLine combines quality and sustainability by ensuring tight and light solutions.
- Beauty Solutions with growth opportunities in tubular & moulded glass and plastics business
- Support our customers' sustainability agenda and route to zero carbon footprint through PCR, most modern furnace technology, light weight and ecoDesigned products

## **Innovative Solutions Provider: Well Underway**

Continuously Enhancing our Portfolio Offering by Best Solutions and Platforms




# Strong Q3 2021 – Financial Update CFO Dr. Bernd Metzner



## Q3 2021: Revenue Growth Accelerated


#### **Operational View on key KPIs**



Organically, adjusted for exchange rate effects as well as acquisitions and divestments

# **Strong Positions Provide Pricing Power**

Q3 2021 Adj. EBITDA Margin Reconciliation in Gx Core Business (in %)



# **Strong Sales Performance in Core Business**

#### Q3 2021: Divisional Performance and Highlights





### **Good Free Cashflow Performance**

#### **Cash Flow and Financial Debt**

				-
In EUR m	Q3 2021	Q3 2020	Change	Comments
Adjusted EBITDA	74.8	75.0	-0.2	EUR ~ -1m negative FX effects
Change in net working capital	23.9	4.7	19.2	Strong improvement of net working capital
Net interest paid	-2.0	-2.3	0.3	
Net taxes paid	-8.6	-8.2	-0.4	
Other	-0.6	-2.5	1.9	
Cash flow from operating activities	87.5	66.7	20.8	
Net capex	-48.7	-29.0	-19.7	High level of investments into growth
Free cash flow before M&A	38.9	37.7	1.2	
Net financial debt <sup>1</sup>	1,018	981	37	
Adj. EBITDA leverage	3.3x	3.2x	0.1x	


<sup>1.</sup> Net financial debt according to credit agreement in force

# 2021 Outlook: Guidance Confirmed CEO Dietmar Siemssen



#### **Guidance Confirmed: Accelerated Revenue Growth**

#### Q4 2021 Projection and Outlook



## **Profitable Growth Accelerating**

#### **Guidance Confirmed – Focus on Absolute Adj. EBITDA Targets**



Due to increasing input prices, we expect to achieve the upper end of our guidance for the financial year 2021 with regards to organic sales growth, while the Adjusted EBITDA margin will be at the lower end.

<sup>1.</sup> The core business consists of the Plastics & Devices and the Primary Packaging Glass divisions; for adj. EBITDA and adj. EPS purposes also including corporate functions/consolidation.

# **Appendix**



## **Financial Calendar**



# Q3 Revenue & Organic Growth Reconciliation

(1 of 4) in EUR m organic growth +10.0% 1.0 382.0 381.0 18.8 15.3 349.2 346.3 -2.9 +12.2% +8.0% Revenue FX P&D **PPG GAT** Revenue Q3 FX Revenue Q3 HQ, Cons. Revenue 03 2020 2020 (FXN) 2021 (FXN) 03 2021 +9.8% 1.0 381.8 380.8 18.8 15.3 349.5 346.7 -2.9 FX Core revenue Core revenue P&D PPG Core revenue FX Core revenue

Q3 2021 (FXN)

Q3 2020 (FXN)

Q3 2020

# YTD Revenue & Organic Growth Reconciliation

(2 of 4) in EUR m organic growth +7.3% 1,064.0 1.061.9 -2.139.5 1,016.0 28.5 -24.0 991.9 +8.7% +5.3% Revenue FX Revenue 9M P&D PPG **GAT** Revenue 9M FX HQ, Cons. Revenue 9M 2020 2020 (FXN) 2021 (FXN) 9M 2021 +6.9% 1,061.1 1,059.0 -2.139.5 1,017.1 28.5 -24.0993.0

PPG

Core revenue

9M 2021 (FXN)

FX

Core revenue

FX

Core revenue


9M 2020 (FXN)

P&D


Core revenue 9M 2020

# Q3 EBITDA & Organic Growth Reconciliation

(3 of 4) in EUR m



# YTD EBITDA & Organic Growth Reconciliation



### **Financial Headroom**

Net financial debt

Adj. EBITDA leverage (x)

(In EUR m)<sup>1</sup>

#### **Net Financial Debt & Adjusted EBITDA Leverage**

#### Net financial debt according to credit agreement in force

## 981 3.2 3.3


Aug-21

Aug-20

	7 13.8 20	7 1018 = 1
In EUR m	Q3 2021	Q3 2020
Drawn portion of the RCF	262	366
Promissory loans (2020)	325	
Promissory loans (2017)	250	250
Promissory loans (2015)	236	425
Local borrowings	42	34
Installment purchase liabilities	3	2
Cash + cash equivalents	-98	-95
Net financial debt <sup>1</sup>	1,018	981

#### **Maturity Profile**

In EUR m



Excluding lease liabilities.

# **Reconciliation Q3 2021**

#### Reported and Adjusted Financials on Group Level

		Q3 2021		Q3 2020	Organic growth YoY <sup>1</sup>
In EUR m	Reported	Adjustment	Adjusted	Adjusted	Adjusted
Revenues	382.0		382.0	349.2	10.0%
EBITDA	69.1	5.7	74.8	75.0	2.1%
Depreciation & Amortization	-34.7	8.7	-26.0	-26.3	
EBIT	34.4	14.4	48.8	48.7	
Financial Result	-5.2	0.0	-5.2	-5.3	
EBT	29.2	14.4	43.6	43.4	
Income Taxes	-8.9	-3.2	-12.1	-12.7	
Non-controlling interests			-1.1	-0.2	
Adj. Net Income			30.4	30.5	5.2%
Adj. EPS			0.97	0.97	5.2%

<sup>1.</sup> Organically, adjusted for exchange rate effects as well as acquisitions and divestments

EBITDA Adjustments of EUR 5.7m mainly driven by Covid-19

## **Reconciliation 9M 2021**

#### **Reported and Adjusted Financials**

		9M 2021		9M 2020	Organic growth YoY <sup>1</sup>
In EUR m	Reported	Adjustment	Adjusted	Adjusted	Adjusted
Revenues	1,061.9		1,061.9	1,016.0	7.3%
EBITDA	196.4	14.5	210.9	210.2	4.6%
Depreciation & Amortization	-100.5	26.6	-73.9	-80.8	
EBIT	95.9	41.1	137.0	129.4	
Financial Result	-13.9	0.0	-13.9	-15.8	
EBT	82.0	41.1	123.1	113.6	
Income Taxes	-23.2	-9.0	-32.2	-31.7	
Non-controlling interests			-2.4	-0.8	
Adj. Net Income			88.5	81.1	16.3%
Adj. EPS			2.82	2.58	16.3%

<sup>1.</sup> Organically, adjusted for exchange rate effects as well as acquisitions and divestments

# **Capex Burdening FCF Performance**

#### **Cash Flow and Financial Debt**

9M 2021	9M 2020	Change	Comments
210.9	210.2	0.6	EUR ~ -3 m negative FX effects
-54.3	-71.0	16.7	Strong working capital improvement
-5.9	-7.0	1.0	
-34.4	-17.7	-16.7	Q2 20 driven by one-time tax effects ( $\Delta$ EUR 15m)
-38.4	-17.4	-21.0	Others mainly impacted by exceptionals in Q1 2021; Q2/Q3 showed a stable development yoy
77.9	97.3	-19.4	
-124.3	-92.5	-31.8	Investments into growth
-46.3	4.8	-51.1	
1,018	981	37	
3.3x	3.2x	0.1x	
	210.9 -54.3 -5.9 -34.4 -38.4 77.9 -124.3 -46.3	210.9       210.2         .54.3       .71.0         .5.9       .7.0         .34.4       .17.7         .38.4       .17.4         77.9       97.3         .124.3       .92.5         -46.3       4.8         1,018       981	210.9       210.2       0.6         .54.3       .71.0       16.7         .5.9       .7.0       1.0         .34.4       .17.7       .16.7         .38.4       .17.4       .21.0         77.9       97.3       -19.4         .124.3       .92.5       .31.8         -46.3       4.8       -51.1         1,018       981       37

<sup>1.</sup> Net financial debt according to credit agreement in force

# gerresheimer

innovating for a better life